Supplementary statement on hepatitis A prevention.
In a recent statement on the prevention of infections caused by hepatitis A virus (HAV), NACI described the usual indications for use of immune serum globulin (IG) and the newly available inactivated hepatitis A vaccine (HAVRIX, SmithKline Beecham). Subsequently, a more potent vaccine formulation was licensed, permitting a single dose primary immunization of adults. This supplementary statement addresses this development and comments on vaccine use in children.
D000328:Adult; D002626:Chemistry, Pharmaceutical; D002648:Child; D006506:Hepatitis A / Q000517:prevention & control*; D022362:Hepatitis A Vaccines; D017957:Hepatitis A Virus, Human / Q000276:immunology*; D006801:Humans; D015164:Vaccines, Inactivated / Q000737:chemistry / Q000600:supply & distribution; D014761:Viral Hepatitis Vaccines / Q000737:chemistry / Q000600:supply & distribution*
D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines